Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal Hemodynamic Effects of Serelaxin in CHF
NCT01546532Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2012
- Primary completion
- Dec 2012
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
A Phase 2 trial of serelaxin in chronic heart failure (CHF), sponsored by Novartis. Started Feb 2012; status: completed.
02
Drugs
serelaxin
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT01546532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01546532.